RESUMO
Melanoma is the most deadly type of skin cancer, constituting annually â¼ 75% of all cutaneous cancer-related deaths due to metastatic spread. Currently, because of metastatic spread, there are no effective treatment options for late-stage metastatic melanoma patients. Studies over the past two decades have provided insight into several complex molecular mechanisms as to how these malignancies evade immunological control, indicating the importance of immune escape or suppression for tumor survival. Thus, it is essential to develop innovative cancer strategies and address immune obstacles with the goal of generating more effective immunotherapies. One important area of study is to further elucidate the role and significance of myeloid-derived suppressor cells (MDSCs) in the maintenance of the tumor microenvironment. These cells possess a remarkable ability to suppress immune responses and, as such, facilitate tumor growth. Thus, MDSCs represent an important new target for preventing tumor progression and escape from immune control. In this study, we investigated the role of MDSCs in immune suppression of T cells in an antigen-specific B16 melanoma murine system utilizing a novel synthetic tyrosinase (Tyr) DNA vaccine therapy in both prophylactic and therapeutic models. This Tyr vaccine induced a robust and broad immune response, including directing CD8 T-cell infiltration into tumor sites. The vaccine also reduced the number of MDSCs in the tumor microenvironment through the downregulation of monocyte chemoattractant protein 1, interleukin-10, CXCL5 and arginase II, factors important for MDSC expansion. This novel synthetic DNA vaccine significantly reduced the melanoma tumor burden and increased survival in vivo, due likely, in part, to the facilitation of a change in the tumor microenvironment through MDSC suppression.
Assuntos
Vacinas Anticâncer/imunologia , Melanoma/imunologia , Melanoma/terapia , Monofenol Mono-Oxigenase/imunologia , Células Mieloides/imunologia , Vacinas de DNA/imunologia , Animais , Linfócitos T CD8-Positivos/imunologia , Linfócitos T CD8-Positivos/metabolismo , Vacinas Anticâncer/administração & dosagem , Citocinas/metabolismo , Modelos Animais de Doenças , Feminino , Humanos , Imunidade Celular , Imunidade Humoral , Imunização , Imunomodulação , Melanoma/genética , Melanoma/mortalidade , Melanoma/patologia , Melanoma/prevenção & controle , Melanoma Experimental , Camundongos , Monofenol Mono-Oxigenase/antagonistas & inibidores , Monofenol Mono-Oxigenase/genética , Células Mieloides/metabolismo , Especificidade do Receptor de Antígeno de Linfócitos T , Carga Tumoral/imunologia , Microambiente Tumoral , Vacinas de DNA/administração & dosagemRESUMO
Gene therapy is an attractive method for the treatment of cardiovascular disease. However, using current strategies, induction of gene expression at therapeutic levels is often inefficient. In this study, we show a novel electroporation (EP) method to enhance the delivery of a plasmid expressing an angiogenic growth factor (vascular endothelial growth factor, VEGF), which is a molecule previously documented to stimulate revascularization in coronary artery disease. DNA expression plasmids were delivered in vivo to the porcine heart with or without coadministered EP to determine the potential effect of electrically mediated delivery. The results showed that plasmid delivery through EP significantly increased cardiac expression of VEGF compared with injection of plasmid alone. This is the first report showing successful intracardiac delivery, through in vivo EP, of a protein expressing plasmid in a large animal.
Assuntos
Doença da Artéria Coronariana/terapia , DNA/administração & dosagem , Eletroporação/métodos , Técnicas de Transferência de Genes , Terapia Genética/métodos , Fator A de Crescimento do Endotélio Vascular/genética , Animais , DNA/genética , Vetores Genéticos , Coração , Plasmídeos/administração & dosagem , Plasmídeos/genética , Biossíntese de Proteínas/genética , Suínos , Fator A de Crescimento do Endotélio Vascular/biossínteseRESUMO
Active and passive immunotherapy targeted at the amyloid-beta (Abeta) peptide has been proposed as therapeutic approach against Alzheimer's disease (AD), and efforts towards the generation and application of antibody-based reagents that are capable of preventing and clearing amyloid aggregates are currently under active investigation. Previously, we selected and characterized a new anti-Abeta1-42 phage-displayed scFv antibody, designated clone b4.4, using a non-immune human scFv antibody library and demonstrated that a peptide based on the sequence of the Ig heavy chain (VH) complementarity-determining region (HCDR3) of this antibody fragment bound to Abeta1-42)and had neuroprotective potential against Abeta1-42 mediated neurotoxicity in rat hippocampal cultured neurons. In the present study, using novel computational methods and in vitro experiments we demonstrated that b4.4 binds to the central region of Abeta1-42. We also demonstrated that this scFv antibody binds to Abeta-derived diffusible ligands (ADDLs) and neutralizes the toxicity of both fibrillar and oligomeric forms of Abeta1-42 tested in vitro in SH-SY5Y cell cultures.
Assuntos
Peptídeos beta-Amiloides/farmacologia , Regiões Determinantes de Complementaridade/farmacologia , Fragmentos de Imunoglobulinas/farmacologia , Cadeias Pesadas de Imunoglobulinas/farmacologia , Fármacos Neuroprotetores/farmacologia , Oligopeptídeos/farmacologia , Fragmentos de Peptídeos/farmacologia , Peptídeos beta-Amiloides/química , Peptídeos beta-Amiloides/imunologia , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Regiões Determinantes de Complementaridade/química , Mapeamento de Epitopos , Humanos , Fragmentos de Imunoglobulinas/química , Cadeias Pesadas de Imunoglobulinas/química , Modelos Moleculares , Fármacos Neuroprotetores/química , Oligopeptídeos/química , Fragmentos de Peptídeos/química , Fragmentos de Peptídeos/imunologia , Ligação ProteicaRESUMO
In vivo electroporation has been used to efficiently deliver drugs and 'therapeutic' genes to tumors, including melanoma lesions. This study reports on the effect of intratumoral delivery of an optimized DNA plasmid expressing interleukin-15 (pIL-15) on established murine melanoma tumors. IL-15 has been demonstrated to have a pivotal role in the function of memory CD8+ T cells and natural killer cells, which are critical for tumor immunosurveillance. In this study, C57BL/6 mice were injected with B16.F10 melanoma cells and randomized into different experimental groups: untreated (P-V-E-), treated with pIL-15 (P+) or backbone plasmid (V+), with or without electroporation (E+ or E-). Treatment was performed intratumorally with 50 microg of plasmid on days 0, 4 and 7 and tumor volume/size, tumor regression and long-term survival were measured. At day 100 after initiation of treatment, the percentage of mice surviving with complete tumor regression in the P-V+E+, P+V-E-, P+V-E+ and P-V-E- treatment groups were 0, 12.5, 37.5 and 0%, respectively. These results demonstrate the ability of pIL-15 to mediate B16 melanoma regression, with the effect being significantly enhanced by electroporative delivery. This is the first description of the ability of a naked DNA plasmid expressing IL-15 to alone mediate complete regression of B16 melanoma tumors and underscores the potential clinical use of these plasmids for the treatment of malignant tumors when delivered with in vivo electroporation.
Assuntos
Interleucina-15/administração & dosagem , Melanoma Experimental/terapia , Plasmídeos , Animais , Eletroporação , Feminino , Injeções Intralesionais , Melanoma Experimental/patologia , Camundongos , Camundongos Endogâmicos C57BLAssuntos
Infecções por HIV/etiologia , Infecções por HTLV-I/etiologia , Morfina/toxicidade , Linhagem Celular , Produtos do Gene gag/metabolismo , Proteína do Núcleo p24 do HIV/metabolismo , Transcriptase Reversa do HIV/metabolismo , HIV-1/efeitos dos fármacos , HIV-1/patogenicidade , Vírus Linfotrópico T Tipo 1 Humano/efeitos dos fármacos , Vírus Linfotrópico T Tipo 1 Humano/patogenicidade , Humanos , Técnicas In Vitro , DNA Polimerase Dirigida por RNA/metabolismo , Proteínas Oncogênicas de Retroviridae/metabolismo , Abuso de Substâncias por Via Intravenosa/complicações , Superinfecção/etiologia , Produtos do Gene gag do Vírus da Imunodeficiência HumanaRESUMO
Streptococcus mutans plays a primary role in the formation of dental caries. Previously, in our laboratory, an S. mutans genomic library was prepared, and the wapA gene was cloned into the shuttle vector, pSA4/4B2. To generate overexpression of wapA and to facilitate efficient purification of the WapA protein for use as an immunogen, an expression vector with the strong tac promoter was used. In order to answer questions regarding the optimization of solubility and expression based on gene size or the hydrophobicity of the protein product, 12 truncated constructs of the wapA gene were prepared using PCR. The truncated products were subcloned into the pGEX-6P-1 glutathione S-transferase (GST) fusion vector and expressed in E. coli BL21. The fusion proteins were analyzed by SDS-PAGE and confirmed by analysis with anti-GST and anti-WapA antibodies. Our study suggests that abrogation of the wapA promoter is necessary for expression of this gene in this expression system. Deletion of the signal peptide and the hydrophobic C terminus of WapA increased expression compared with the full-length construct, and truncation at the protease cleavage site of the C-terminal region greatly increased the stability of the protein without a loss in reactivity with the anti-WapA antibody. Western immunoblot analysis with anti-WapA antiserum clearly showed that the majority of the epitopes of the GST-WapA fusions are located in the N-terminal region of WapA. The immunogenicity of the various WapA fusion products is being examined in mice and rats to further map the immunologically dominant regions of the protein. This method effectively increased the expression of WapA and should contribute to the further understanding of gene expression of E. coli, as well as aid in the characterization of this protein for future immunologic evaluation.
Assuntos
Antígenos de Bactérias , Proteínas de Bactérias/genética , Cárie Dentária/microbiologia , Streptococcus mutans/genética , Western Blotting , Escherichia coli/genética , Regulação Bacteriana da Expressão Gênica , Glutationa Transferase/genética , Glutationa Transferase/metabolismo , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/metabolismo , Deleção de SequênciaRESUMO
Previously, we generated human monoclonal antibodies using peripheral blood mononuclear cells from an asymptomatic human immunodeficiency virus type 1 (HIV-1)-seropositive donor. One of these monoclonal antibodies (designated clone 3, CL3) recognized 10 amino acids (GCSGKLICTT) within the immunodominant region (cluster I) of the transmembrane envelope glycoprotein gp41 and neutralized infection of target cells with different laboratory isolates. Because the epitope recognized by CL3 has two cysteine residues that could potentially produce a disulfide loop in gp41, we analyzed binding of our monoclonal antibody to the cyclic and linear motif of the peptide sequence IWGCSGKLICTTAVP (residues 600-614). The CL3 antibody did not bind to the synthetic cyclic peptide but did recognize the linear form. Two polyclonal rabbit sera against both the linear and cyclic peptides were then generated. Both antisera bound to viral glycoproteins gp41 and gp160, but neither sera neutralized HIV-1 laboratory isolates. Using a set of alanine-substituted IWGCSGKLICTTAV peptides, we analyzed binding of polyclonal antisera and CL3. The profile of binding of polyclonal antisera to these peptides was different from that of CL3 to the same peptides. This suggests that CL3 recognized a unique neutralizable core epitope, which was not immunogenic in either the cyclic or the linear IWGCSGKLICTTAVP peptides used as immunogens in the rabbits.
Assuntos
Antígenos HIV/imunologia , Proteína gp41 do Envelope de HIV/imunologia , HIV-1/imunologia , Epitopos Imunodominantes/imunologia , Sequência de Aminoácidos , Substituição de Aminoácidos , Animais , Anticorpos Monoclonais/imunologia , Especificidade de Anticorpos/imunologia , Linhagem Celular , Cisteína/imunologia , Cisteína/metabolismo , Dissulfetos/imunologia , Dissulfetos/metabolismo , Antígenos HIV/química , Proteína gp160 do Envelope de HIV/imunologia , Proteína gp41 do Envelope de HIV/química , Soropositividade para HIV/imunologia , Soropositividade para HIV/virologia , HIV-1/genética , HIV-1/fisiologia , Humanos , Soros Imunes/imunologia , Epitopos Imunodominantes/química , Dados de Sequência Molecular , Testes de Neutralização , Peptídeos Cíclicos/síntese química , Peptídeos Cíclicos/química , Peptídeos Cíclicos/imunologia , Coelhos , Replicação ViralRESUMO
DNA vaccines have a demonstrated ability to induce humoral and cellular immune responses in animal models and humans. The technology, although it dates back to the 1950's, has had an insurgence of interest within the past few years following concurrent research papers. The basic technology is being applied broadly to viral, bacterial and parasitic infections. It has also been demonstrated that genes delivered via plasmid expression vectors result in expression of functional proteins in the inoculated host. Further, injection of plasmids encoding cytokine, chemokine or co-stimulatory molecules, also referred to as immunomodulatory plasmids can lead to the further expansion of this technology to include directed immunology. We have been developing DNA technology specifically with a focus as a vaccine against HIV-1 infection. We report that such vaccines can stimulate immune responses in a variety of relevant animal systems including humoral and cellular responses as well as the production of beta-chemokines. We describe that the beta-chemokines can both modulate the immune response induced by DNA vaccines and be modulated by the DNA vaccines in the murine and chimpanzee models as well as in humans.
Assuntos
Vacinas contra a AIDS , Quimiocinas/imunologia , DNA Viral/imunologia , HIV-1/genética , Animais , Ensaios Clínicos como Assunto , Feminino , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Pan troglodytes , Células Tumorais CultivadasRESUMO
Altered levels of Type 1 and Type 2 cytokines are important in retrovirus-induced immunosuppression. The combination of immunostimulatory agents with antiviral drugs alters the course of murine retroviral infections. Previously, it was demonstrated that in vitro treatment of noninfected splenocytes and in vivo treatment of Friend leukemia virus (FLV)-infected mice with the combination of azidothymidine (AZT) and methionine enkephalin (MENK) significantly increases Type 1 cytokine levels and decreases Type 2 cytokines compared with treatment with only AZT. In order to study the effect of the time of initiation of immunomodulation on the course of retroviral infections, we examined the kinetics of cytokine production by isolated splenocytes from infected mice. BALB/c mice were infected with FLV, and spleen cells were removed at specified times postinfection (days 1, 3, 7, 10, and 14). Interleukin (IL)-2, interferon (IFN-gamma, IL-4, and IL-10 production by unstimulated or ConA-stimulated splenocytes treated in vitro with AZT, MENK, or AZT + MENK was determined after 48 h. The capacity of the isolated splenocytes to produce the Type 1 cytokines IL-2 and IFN-gamma in response to stimulation with ConA and combination therapy decreased over the course of infection. These results suggest that MENK treatment initiated later in the course of infection is unable to modulate the cytokine profile and would likely be ineffective in altering the course of FLV induced-disease. The results indicate the necessity to initiate antiretroviral therapy early in infection. Such information may be applicable in designing future regimens for HIV-1 infections in humans.
Assuntos
Citocinas/biossíntese , Vírus da Leucemia Murina de Friend , Infecções por Retroviridae/tratamento farmacológico , Baço/metabolismo , Animais , Células Cultivadas , Concanavalina A/farmacologia , Encefalina Metionina/uso terapêutico , Feminino , Interferon gama/biossíntese , Interleucina-2/biossíntese , Camundongos , Camundongos Endogâmicos BALB C , Infecções por Retroviridae/imunologia , Baço/imunologia , Fatores de Tempo , Zidovudina/uso terapêuticoRESUMO
Human T-cell leukemia virus type I (HTLV-I) infection is emerging as an important complication in HIV infection and AIDS in injecting drug users. HIV-1 and HTLV-I share a common host in CD4+ T lymphocytes. However, the result of HIV-1 infection is the decimation of this cell population, whereas a hallmark of HTLV-I infection is the inappropriate proliferation of infected cells. Combined epidemiologic data suggest that HTLV-I infection is enhanced during concurrent HIV-1/HTLV-I infection; however, there are currently no in vitro studies focusing on the effects of drugs of abuse on retrovirus coinfection. We have found that in an in vitro coinfection system (HIV-1 + HTLV-I), morphine treatment further enhanced the levels of HTLV-I p19. In addition, indicators of in vitro infection by cell-free HIV-1 were reduced by morphine treatment in both single and dual in vitro infection experiments. Interleukin 2 levels in the affected cultures were found to increase with combined HTLV-I infection and morphine treatment. These in vitro results indicate the need to further explore the activity of HTLV-I within opiate-treated cells, as this oncoretrovirus appears to be especially sensitive to morphine-induced alterations to its host cell environment.
Assuntos
HIV-1/efeitos dos fármacos , Vírus Linfotrópico T Tipo 1 Humano/efeitos dos fármacos , Morfina/farmacologia , Linhagem Celular , Efeito Citopatogênico Viral , Produtos do Gene gag/biossíntese , HIV-1/fisiologia , Vírus Linfotrópico T Tipo 1 Humano/fisiologia , Humanos , Interleucina-2/biossíntese , Proteínas Oncogênicas de Retroviridae/biossíntese , Produtos do Gene gag do Vírus da Imunodeficiência HumanaRESUMO
Granulocyte-macrophage colony-stimulating factor (GM-CSF) could in theory attract antigen-presenting cells in muscle following intramuscular DNA immunization, resulting in enhanced antigen-specific immune responses. Thus, such adjuvants could constitute an important addition to a herpes vaccine by amplifying specific immune responses. Here we investigate the utility of GM-CSF cDNA as a vaccine adjuvant for herpes simplex virus (HSV)-2 in a mouse challenge model. GM-CSF cDNA co-injection enhanced levels of specific IgG, IgE and IgA against HSV-2 gD protein significantly higher than gD plasmid vaccination alone. Moreover, GM-CSF co-injection induced a dramatic increase in IgG1 levels, as compared to IgG2a levels, suggesting a Th2 bias in the response. T helper cell proliferation and secretion of cytokines (IL-2 and IFN-gamma) were significantly increased by GM-CSF cDNA co-injection. When challenged with a lethal dose of HSV-2, GM-CSF co-injection increased survival rates to 90%, an improvement as compared to gD vaccination alone (60-63%). Furthermore, GM-CSF cDNA co-injection reduced herpetic lesions and resulted in a faster recovery from lesions. These data indicate that GM-CSF cDNA enhances both humoral and cellular immune responses and enhances vaccine efficacy, resulting in reduced HSV-2-derived morbidity as well as mortality.
Assuntos
Fator Estimulador de Colônias de Granulócitos e Macrófagos/genética , Herpesvirus Humano 2/imunologia , Células Th1/imunologia , Células Th2/imunologia , Vacinas de DNA/imunologia , Proteínas do Envelope Viral/imunologia , Vacinas Virais/imunologia , Animais , Formação de Anticorpos , Citocinas/biossíntese , Feminino , Herpes Genital/imunologia , Ativação Linfocitária , Camundongos , Camundongos Endogâmicos BALB CRESUMO
The transmission and progression of the human retroviruses HIV-1 and HTLV-1/2 can be most likely influenced by a variety of "lifestyle cofactors" which includes the use of certain injected pharmaceuticals. Some investigations have suggested that HIV-1 infected individuals who are injecting drug users (IDUs) may undergo an accelerated rate of progression to AIDS. It is known that opioid receptors exist on cells pertinent to immune function, and that the activation or inhibition of these receptors may enhance or down-regulate some cell activities. The mechanisms for these effects have not yet been elucidated, nor have the effects of opioids on retroviral infection models been fully determined. While some work has been performed on the effects of opiates on infection by HIV-1 and SIV virtually no work has been done on the potential effects of this class of drugs on HTLV-1 and 2 infection. The potential effects of opiates on these retroviruses are important because of the higher incidence of infection in IDUs. Because IDUs compose one of the emerging high risk populations for infection with HIV-1 and more recently HTLV it is relevant to analyze the direct and indirect effects of opioids on the progression of retroviral infections. Our preliminary results from in vitro syncytia formation studies suggest a modulation by opioid-selective receptor agonists of in vitro infection by both HIV-1 and HTLV-I. These initial results underscore the necessity for further studies to define and elucidate the role of opiate abuse in the infection by human retroviruses as well as the associated pathogenesis.
Assuntos
HIV-1/efeitos dos fármacos , Vírus Linfotrópico T Tipo 1 Humano/efeitos dos fármacos , Morfina/farmacologia , Linhagem Celular , Sistema Livre de Células , Relação Dose-Resposta a Droga , Células Gigantes/efeitos dos fármacos , Células Gigantes/virologia , HumanosRESUMO
The exact mechanism by which the human T cell leukemia viruses (HTLV) infects target cells remains unclear; although some molecules have been identified to be important in viral infection and entry. To investigate these phenomena, we generated a panel of monoclonal antibodies (MAb) against a B cell line (BJAB-WH) which is highly permissive for infection with HTLV. These MAb have been used to further characterize the membrane molecules important for HTLV infection. Three of these MAb designated 4.2.3, 3.3.10, and 11.2.3 were capable of inhibiting syncytium formation induced in human B and T cell lines (i.e., BJAB-WH and SupT-1, respectively) by co-culture with HTLV-I infected MT-2 cells. All of these MAbs immunoprecipitated a 80-85 kDa antigen from the lysates of metabolically labeled BJAB-WH but not from BJAB-CC/84, a noninfectible target cell. The binding of these MAb with different HTLV target cells was analyzed and compared with binding of polyclonal monospecific antisera to the same cell lines. A 80-85 kDa membrane glycoprotein was isolated with an immunoaffinity chromatographic column constructed with MAbs 4.2.3 and 3.3.10. This cellular antigen was capable of inhibiting HTLV I/MT-2 induced fusion. This is the first direct demonstration that a 80-85 kDa cellular glycoprotein is directly involved in HTLV I/II infection and syncytium formation.
Assuntos
Antígenos de Superfície/imunologia , Glicoproteínas/imunologia , Infecções por HTLV-I/imunologia , Anticorpos Monoclonais , Fusão Celular/imunologia , Infecções por HTLV-I/etiologia , Humanos , Receptores de Superfície Celular/imunologiaAssuntos
Vírus Linfotrópico T Tipo 1 Humano/imunologia , Plasmídeos/imunologia , Vacinação/métodos , Vacinas de DNA/imunologia , Vacinas Virais/imunologia , Animais , Desenho de Fármacos , Vírus Linfotrópico T Tipo 1 Humano/genética , Vírus Linfotrópico T Tipo 1 Humano/patogenicidade , Vírus Linfotrópico T Tipo 1 Humano/fisiologia , HumanosRESUMO
The role of the immune response in controlling human immunodeficiency virus type 1 (HIV-1) replication is controversial. Immunotherapeutic strategies that have the ability to broaden immune responses might play a role in slowing disease progression. DNA immunization was studied as immunotherapy in infected chimpanzees. Two HIV-1-infected chimpanzees were vaccinated with DNA plasmid vaccines, one with plasmid pCMN160, which expresses the envelope glycoprotein of HIV-1MN and rev, and the other with a control plasmid. The chimpanzee immunized with pCMN160 demonstrated enhanced humoral responses. Virus load was monitored. Virus load in the chimpanzee receiving pCMN160 decreased at week 20 and has remained at background levels. The control chimpanzee was subsequently vaccinated with pCMN160. After immunization, the antibody responses increased and, as in the first animal, the virus load decreased. These results indicate the potential of the immune response to have a direct impact on HIV-1 replication in chimpanzees.
Assuntos
Produtos do Gene rev/genética , Proteína gp160 do Envelope de HIV/genética , Infecções por HIV/imunologia , Infecções por HIV/terapia , HIV-1 , Vacinas de DNA/uso terapêutico , Sequência de Aminoácidos , Animais , Antígenos CD28/imunologia , Linfócitos T CD8-Positivos/imunologia , Células Cultivadas , Técnicas de Cocultura , DNA Viral/análise , DNA Viral/genética , Produtos do Gene rev/imunologia , Anticorpos Anti-HIV/sangue , Anticorpos Anti-HIV/imunologia , Proteína gp160 do Envelope de HIV/imunologia , Infecções por HIV/virologia , HIV-1/fisiologia , Imunoterapia Ativa , Leucócitos Mononucleares/imunologia , Leucócitos Mononucleares/virologia , Contagem de Linfócitos , Dados de Sequência Molecular , Pan troglodytes , Peptídeos/genética , Peptídeos/imunologia , Plasmídeos , Reação em Cadeia da Polimerase , Proteínas Recombinantes/imunologia , Vacinas de DNA/administração & dosagem , Carga Viral , Produtos do Gene rev do Vírus da Imunodeficiência HumanaRESUMO
We have previously reported that the human immunodeficiency virus type 1 (HIV-1) regulatory gene vpr induces differentiation of rhabdomyosarcoma (embryonal muscle tumor cell line) cells, an effect that is accompanied by reduced proliferative capacity of the transfected cells. In this report, we examine the effect of Vpr expression on several different tumor cell lines derived from unique lineages. These tumor cells display different patterns of modulated oncogenes including both ras and p53 mutations. Here we demonstrate that the growth of tumor cells in vitro and in vivo is arrested by the expression of HIV-1 Vpr. Expression of Vpr in several human tumor cell lines upon transfection resulted in an accumulation of cells in the G2/M phase of cell cycle with altered cellular morphology, including an increase in adherence, and growth arrest, consistent with a differentiated phenotype. Vpr expression in B78/H1 cells results in a marked reduction in colony formation in vitro and an associated reduction in melanin synthesis by the cells. Vpr-transfected melanoma cells inoculated into syngenic C57BL/6 mice showed a markedly reduced ability to form tumors in vivo. These results suggest that this retroviral regulatory gene has broad tumor suppressor effects, likely mediated by transcriptional regulation of the state of the host cell.
Assuntos
Produtos do Gene vpr/fisiologia , Genes Supressores de Tumor/fisiologia , HIV-1 , Neoplasias Experimentais/patologia , Animais , Ciclo Celular/fisiologia , Divisão Celular , Linhagem Celular , Fibroblastos , Expressão Gênica , Produtos do Gene vpr/genética , Genes p53/fisiologia , Humanos , Neoplasias Pulmonares/secundário , Melaninas/biossíntese , Melanoma/metabolismo , Melanoma/patologia , Camundongos , Camundongos Endogâmicos C57BL , Neoplasias Experimentais/metabolismo , Oncogenes , Ratos , Transfecção , Células Tumorais Cultivadas , Produtos do Gene vpr do Vírus da Imunodeficiência HumanaRESUMO
We have previously reported on the generation of specific functional immune responses after inoculation of animals with expression vectors encoding HIV-1 genes. This article provides the details of the first application of this new technology to induce immune responses against HIV-2. This virus is molecularly and serologically distinct from HIV-1 and is in fact more closely related to the simian immunodeficiency virus (SIV). Anti-HIV-2 and SIV antibodies were induced in mice of three different haplotypes following a single intramuscular inoculation with an HIV-2/ROD envelope glycoprotein expression vector (pcEnv-2). Boosting of animals with pcEnv-2 induced both anti-HIV-2 neutralizing antibodies and T cell-proliferative responses against HIV-2 and SIVmac proteins. We compared the humoral and cellular immune responses of mice injected with pcEnv-2 and then boosted with either the homologous DNA construct or a recombinant Env protein. Animals boosted with pcEnv-2 generated B and T cell immune responses as strong as those of mice boosted with recombinant gp140 protein in adjuvant. Finally, cellular immune responses were significantly increased with the coadministration of pcEnv-2 and a plasmid expressing interleukin 12. We therefore conclude that DNA plasmid inoculation induces cross-reactive anti-HIV-2 and anti-SIVmac immune responses in mice. This technology should be further investigated as a potential vaccine component for this human pathogen.
Assuntos
Vacinas contra a AIDS/imunologia , DNA Viral/imunologia , Anticorpos Anti-HIV/imunologia , HIV-2/imunologia , Vírus da Imunodeficiência Símia/imunologia , Vacinas de DNA/imunologia , Vacinas Sintéticas/imunologia , Animais , Células COS , Linhagem Celular , Chlorocebus aethiops , Reações Cruzadas , Feminino , Anticorpos Anti-HIV/biossíntese , Humanos , Camundongos , Camundongos Endogâmicos AKR , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Plasmídeos , Linfócitos T/imunologia , Células Tumorais CultivadasRESUMO
Nucleic acid or DNA immunization represents a novel approach to vaccine and immune therapeutic development. The direct injection of expression cassettes into a living host results in in vivo gene expression and immune activation. In the case of HIV-1 it has been shown by our laboratory that facilitated injection mimicks aspects of live attenuated vaccines and that both humoral and cellular responses can be induced upon injection of a nucleic acid sequence directly into a host target tissue. Antisera from HIV-1 plasmid expression cassette-immunized animals contain anti-HIV envelope glycoprotein immune responses. The antiserum neutralizes HIV-1 infection and inhibits cell to cell infection in vitro. Cellular immune responses have also been evaluated. We observed both T cell proliferation and isotype switching consistent with the production of relevant T helper immune responses in immunized animals. Furthermore it was demonstrated that CTL lysis of relevant env-expressing targets was similarly induced. These studies further define the importance of evaluating this new technology for vaccine and immune therapeutic development for HIV-1 as well as for other human viral pathogens.
Assuntos
Vacinas contra a AIDS/imunologia , DNA Recombinante , Produtos do Gene env/imunologia , Vetores Genéticos , Anticorpos Anti-HIV/biossíntese , HIV-1/imunologia , HIV-2/imunologia , Precursores de Proteínas/imunologia , Proteínas Recombinantes de Fusão/imunologia , Linfócitos T Citotóxicos/imunologia , Vacinas Sintéticas/imunologia , Animais , Especificidade de Anticorpos , Vírus do Sarcoma Aviário/genética , Produtos do Gene env/genética , Anticorpos Anti-HIV/imunologia , Proteína gp160 do Envelope de HIV , Humanos , Ativação Linfocitária , Macaca fascicularis/imunologia , Camundongos , Testes de Neutralização , Precursores de Proteínas/genética , Proteínas Recombinantes de Fusão/genética , Sequências Repetitivas de Ácido Nucleico , Células Th1/imunologiaRESUMO
DNA inoculation has the potential to produce antigens in a native as well as a host-"customized" form for presentation to the immune system. As such this technology may have relevance for vaccine/immune therapeutic strategies for a variety of infectious pathogens. In rodents in vivo inoculation of plasmid expression vectors encoding HIV-1 gene products leads to production of HIV-1 antigens in vivo, resulting in the production of both cellular and humoral immune responses. In primates only preliminary studies of serology have been reported. Here we report further evaluation of this new technology as a method to induce humoral and particularly cellular immune responses against a human pathogen, the HIV-1 virus, in nonhuman primates. Following inoculation and boosting of animals with an HIV gp160 plasmid expression vector we observed the induction of neutralizing responses against two diverse HIV-1 isolates in 2 of 3 vaccinated animals. T cell proliferative responses to HIV antigens were also observed in all plasmid-inoculated animals and specific cross-reactive cytotoxic T lymphocyte responses were developed in vaccinated animals. This report establishes the ability of DNA inoculation to induce cellular immune responses in nonhuman primates and suggests that further investigation of this technology with regard to human vaccine or immune therapeutic development is therefore warranted.
Assuntos
Vacinas contra a AIDS/imunologia , DNA Viral/imunologia , Produtos do Gene env/imunologia , Antígenos HIV/imunologia , HIV-1/imunologia , Precursores de Proteínas/imunologia , Linfócitos T/imunologia , Animais , Formação de Anticorpos , Linhagem Celular , Genes Virais , Anticorpos Anti-HIV/biossíntese , Anticorpos Anti-HIV/imunologia , Antígenos HIV/biossíntese , Proteína gp160 do Envelope de HIV , HIV-1/fisiologia , Humanos , Imunidade Celular , Ativação Linfocitária , Macaca fascicularis , Masculino , Testes de Neutralização , Plasmídeos , Roedores , Linfócitos T Citotóxicos/imunologiaRESUMO
Direct DNA inoculation is the basis for a new technology that has been successfully used for in vivo induction of both humoral and cellular immune responses. However, the immunological parameters of this new approach remain to be evaluated in detail. We report here that direct DNA inoculation can induce protection from malignant tumor cell challenge through the generation of specific immune responses directed against antigens displayed on the tumor cells. The protected mice remain tumor-free for more than 1 year post-challenge. Memory responses upon tumor rechallenge were observed for both humoral and cellular immunity. Inoculated animals were able to reject otherwise lethal tumors several months following the original DNA inoculation protocol. These in vivo protective responses suggest that further analysis of this technology for vaccine development or immune therapeutic strategies is warranted.